UBS analyst Danielle Antalffy raised the firm’s price target on Inspire Medical to $405 from $395 and keeps a Buy rating on the shares. Inspire remains one of the firm’s highest-conviction ideas following another strong double-digit beat and raise, the analyst tells investors in a research note. The firm thinks Inspire will continue its trend of delivering sales upside.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- Inspire Medical raises FY23 revenue view to $600M-$610M from $580M-$590M
- Inspire Medical reports Q2 EPS (41c), consensus (57c)
- Inspire Medical Systems, Inc. Announces Second Quarter 2023 Financial Results and Updates 2023 Outlook
- Inspire Medical appoints Charisse Sparks as CMO
- Is INSP a Buy, Before Earnings?